Drug Profile
AZD 5106
Latest Information Update: 10 Mar 2004
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class
- Mechanism of Action Neurokinin 2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Overactive bladder
Most Recent Events
- 30 Jan 2004 Discontinued - Preclinical for Overactive bladder in Europe (unspecified route)
- 20 Feb 2001 New profile
- 20 Feb 2001 Preclinical development for Overactive bladder in Europe (Unknown route)